ClinicalTrials.gg

Program

cilofexor

Also written as “Cilofexor”, “CILO” and “Cilofexor Dose B”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Cholangitis, Sclerosing · Liver Cirrhosis, Biliary, led by 2 companies.

Furthest: phase 3, since Mar 25, 201913 company-led studies, 1 open or runningNext primary completion: Dec 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences121 open or runningphase 3since Mar 25, 2019Jan 11, 2016Dec 2028phase 2 · NCT07841977
Phenex Pharmaceuticals10 open or runningphase 2since Nov 19, 2013Nov 19, 2013none ahead

Also a collaborator on its studies: Novo Nordisk.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 19, 2013First study: phase 2 study in Non-alcoholic Fatty Liver DiseaseNew to Phenex PharmaceuticalsPhenex Pharmaceuticals · NCT01999101 · 12 enrolled · Austria
  2. Jan 11, 2016Gilead Sciences's first study: phase 1 study in Non-alcoholic Fatty Liver DiseaseNew to Gilead SciencesGilead Sciences · NCT02654002 · 120 enrolled · United States
  3. May 20, 2016Phase 2 study in Non-alcoholic Fatty Liver DiseaseGilead Sciences · NCT02781584 · 220 enrolled · United States, New Zealand
  4. Jun 13, 20162 phase 2 studiesGilead Sciences · NCT02943460, NCT02943447
  5. Jun 17, 2016Phase 1 study in Non-alcoholic Fatty Liver DiseaseGilead Sciences · NCT02808312 · 57 enrolled · United States, New Zealand
  6. Jul 29, 2016Phase 2 study in Non-alcoholic Fatty Liver DiseaseGilead Sciences · NCT02854605 · 140 enrolled · United States, Canada, Hong Kong and more
  7. Feb 23, 2018Phase 2 study in Non-alcoholic Fatty Liver DiseaseGilead Sciences · NCT03449446 · 395 enrolled · United States, Australia, Canada and more
  8. Mar 25, 2019Phase 3 study in Cholangitis, SclerosingGilead Sciences · NCT03890120 · 419 enrolled · United States, Australia, Austria and more
  9. Jun 12, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseGilead Sciences · NCT03987074 · 109 enrolled · United States
  10. Aug 15, 2019Phase 1 study in Cholangitis, SclerosingGilead Sciences · NCT04060147 · 11 enrolled · United States
  11. Jul 20, 2021Phase 2 study in Non-alcoholic Fatty Liver DiseaseGilead Sciences · NCT04971785 · 457 enrolled · United States, Australia, Canada and more
  12. Sep 21, 2026Phase 2 study in Liver Cirrhosis, BiliaryGilead Sciences · NCT07841977 · 132 planned · United States

Ahead

  1. Dec 2028Primary completion: phase 2 study in Liver Cirrhosis, BiliaryGilead Sciences · NCT07841977

TargetBeta

NR1H4 →read by rule
“Bile acid receptor FXR agonist”ChEMBL 37, by rule

Other programs on NR1H4

ProgramCompanyFurthest phaseStudies
LY4395089Eli Lillyphase 23

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07841977Liver Cirrhosis, Biliary · United States2RecruitingGilead SciencesDec 2028132
NCT04971785Non-alcoholic Fatty Liver Disease · United States, Australia, Canada and more2CompletedGilead SciencesNov 12, 2024457
NCT04060147Cholangitis, Sclerosing · United States1TerminatedGilead SciencesSep 2, 202111
NCT03987074Non-alcoholic Fatty Liver Disease · United States2CompletedGilead SciencesJul 13, 2020109
NCT03890120Cholangitis, Sclerosing · United States, Australia, Austria and more3TerminatedGilead SciencesNov 10, 2022419
NCT03449446Non-alcoholic Fatty Liver Disease · United States, Australia, Canada and more2CompletedGilead SciencesOct 30, 2019395
NCT02854605Non-alcoholic Fatty Liver Disease · United States, Canada, Hong Kong and more2CompletedGilead SciencesJan 9, 2018140
NCT02808312Non-alcoholic Fatty Liver Disease · United States, New Zealand1CompletedGilead SciencesOct 16, 201857
NCT02943460Cholangitis, Sclerosing · United States, Austria, Canada and more2CompletedGilead SciencesFeb 28, 201852
NCT02943447Liver Cirrhosis, Biliary · United States, Austria, Canada and more2TerminatedGilead SciencesSep 4, 201971
NCT02781584Non-alcoholic Fatty Liver Disease · United States, New Zealand2CompletedGilead SciencesDec 17, 2020220
NCT02654002Non-alcoholic Fatty Liver Disease · United States1CompletedGilead SciencesJul 14, 2016120
NCT01999101Non-alcoholic Fatty Liver Disease · Austria2CompletedPhenex PharmaceuticalsJan 201512

How it is read

Names in the registry

  • “Cilofexor”, 7 entries
  • “CILO”, 2 entries
  • “Cilofexor Dose B”, 1 entry
  • “Cilofexor Dose A”, 1 entry
  • “Cilofexor (CILO)/Firsocostat (FIR)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.